Mouse IL-6 ELISPOT antibody pair
- Known as:
- Mouse Interleukin-6 ELISPOT (anti-) pair
- Catalog number:
- CT486-20
- Product Quantity:
- 20-plate
- Category:
- -
- Supplier:
- U-CyTech
- Gene target:
- Mouse IL-6 ELISPOT antibody pair
Related genes to: Mouse IL-6 ELISPOT antibody pair
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: Mouse IL-6 ELISPOT antibody pair
Related articles to: Mouse IL-6 ELISPOT antibody pair
- Inflammation is a primary driver of skin ageing. Mussel mucin, a naturally occurring anti-inflammatory protein, suffers from inefficient extraction from its natural source. To overcome the yield limitation of natural sources and to verify the biological activity of the recombinant protein, this study employed synthetic biology techniques to efficiently produce and purify the recombinant mussel mucin Mfp151 and subsequently evaluated its anti-inflammatory and skin barrier repair functions. Using human immortalized keratinocytes (HaCaT), human foreskin fibroblasts (HFF-1), and human monocyte leukemia cells (THP-1) as models, we assessed the skin-repairing, antioxidant, and anti-inflammatory effects of Mfp151 the CCK-8 assay, qPCR, transmembrane resistance measurement, scratch assay, ELISA, and free radical scavenging assays. In vivo validation was conducted with a zebrafish sunburn model. The results demonstrated that Mfp151 significantly promoted cell proliferation (80 μg/mL treatment increased HaCaT cell proliferation by approximately 32%) and migration, while upregulating the expression of key skin barrier genes , , and by 2.14-3.88 folds. Mfp151 effectively scavenged DPPH and ABTS free radicals while enhancing cellular antioxidant capacity by activating the Nrf2 pathway. Regarding anti-inflammatory effects, Mfp151 significantly suppressed lipopolysaccharide-induced production of pro-inflammatory factors IL-6, TNF-α, and IL-1β (80 μg/mL treatment reduced expression levels to 59.87%-79.12% of that in the model group), while significantly downregulating the expression of key inflammatory mediators COX-2 and iNOS and their downstream product PGE2 (80 μg/mL treatment reduced , expression and PGE2 secretion to 48.91%-67.30% those in the model group.) Zebrafish experiments confirmed the significant promotion of Mfp151 on caudal fin repair following sunburn. The data indicate that the recombinant Mfp151 obtained through synthetic biology techniques possesses skin-repairing functions alongside antioxidant and anti-inflammatory activities, thus demonstrating promising application prospects in fields such as anti-ageing cosmetic ingredients and wound dressings. - Source: PubMed
Zhang ChaoLi QuanfeiPan LiangWang YuFang MingyuanShao ZhengyangChen QianHe KundongLei PengGu Yi'anSun LiangZhan YijingLu QianjinXu HongWang Rui - CC-chemokine ligand 2 (CCL2) plays pivotal roles in many osteoimmune disorders, while its role in peri-implantitis is unknown. The main research question aimed to address in this study is investigating the specific roles of CCL2 in peri-implantitis and assessing the preventive and therapeutic effects of bindarit on experimental peri-implantitis. - Source: PubMed
Publication date: 2026/07/29
Zhou AnqiWei YipingJiang WentingYuan ShashaYang TingMo YaqianWang XuekangLi QingqingSong ZhanmingLiu ZhongtianLi NingZhang ZhaohuaiWang YingHu Wenjie - The development of functional dairy foods using probiotic cultures with additional nutritional benefits has gained considerable attention. Limosilactobacillus reuteri NCDC 958 (LRN958) has been identified as a probiotic strain with the ability to produce vitamin B; however, establishing its safety profile is essential for its successful application in food and human use. In this study, the preclinical safety of the vitamin B-producing LRN958 strain was assessed using integrated in vitro and in vivo approaches. In vitro evaluation revealed that the strain lacked virulence-associated genes, did not produce biogenic amines or degrade mucin, and was susceptible to recommended antibiotics. In vivo safety was examined through acute, sub-acute, and sub-chronic oral toxicity studies in mice. Administration of LRN958 caused no mortality or clinical signs of toxicity. Body weight, hematological and biochemical parameters, organ indices, and histopathology remained comparable to controls. No bacterial translocation was observed, and immune markers, including IgA, IgG, IL-10, TGF-β, IL-6, and TNF-α, which showed no significant differences, indicating maintained immune homeostasis. The no-observed-effect level (NOEL) was 10 CFU/mouse/day. Overall, the findings confirm that LRN958 is safe, non-pathogenic, and supports its potential clinical use and application in probiotic and functional food formulations. - Source: PubMed
Salini S VNarsimlu BattulaJoseph AngelaKumari ManoramaBehare Pradip V - Resistance to 5-fluorouracil (5-FU) necessitates its administration in combination with other drugs to enhance the clinical outcome. Oxymatrine (OMT) exhibits antitumor and anti-inflammatory activities. This study aimed to investigate the synergistic antitumor effect of OMT with 5-FU in A549 cells. - Source: PubMed
Publication date: 2026/07/25
Zeng GuofangLuo FeiZeng QiaoliWang ZhiqiangGuo Runmin - Jiuwei Xiaozhi Decoction (JWXZ) is a nine-herb traditional Chinese medicine formula clinically used for hepatic steatosis and dyslipidemia, but its chemical basis and pharmacological mechanisms in metabolic dysfunction-associated steatotic liver disease (MASLD) remain incompletely defined. The chemical profile of JWXZ was characterized by UHPLC-HRMS/MS. Its therapeutic effects were evaluated in a high-fat diet (HFD)-induced mouse model of MASLD, followed by hepatic transcriptomic analysis, network pharmacology, molecular docking, Western blotting, and immunofluorescence validation. UHPLC-HRMS/MS identified 178 chemical constituents in JWXZ, including phenolic acids, flavonoids, flavonoid glycosides, alkaloids, isoflavones, and coumarins. In HFD-fed mice, JWXZ attenuated body weight gain, white adipose accumulation, dyslipidemia, hepatic triglyceride and cholesterol accumulation, serum transaminase elevation, and hepatic steatosis, while improving glucose tolerance and partially restoring whole-body metabolic flexibility. Hepatic transcriptomics identified 124 HFD-dysregulated genes reversed by high-dose JWXZ, with prominent enrichment in cholesterol and sterol biosynthesis, endoplasmic reticulum proteostasis, oxidative stress response, and PPARα-related lipid handling. Integrated transcriptomic and network pharmacology analyses further identified 157 shared targets and 18 overlapping pathways, converging mainly on cholesterol metabolism and PPAR signaling. Protein-level validation showed that JWXZ suppressed SREBP2 proteolytic activation, reduced nuclear SREBP2 abundance, and downregulated HMGCR, SQLE, and PCSK9, indicating inhibition of the hepatic cholesterogenic program. In parallel, JWXZ restored nuclear PPARα abundance and CPT1A expression, consistent with reactivation of fatty acid oxidation. JWXZ also reduced hepatic EGFR phosphorylation and lowered hepatic and circulating TNF-α, IL-6, IL-1β, and MCP-1 levels. Molecular docking provided supportive evidence for potential interactions between representative JWXZ constituents and key regulators, including naringin-HMGCR, chlorogenic acid-SQLE, rhoifolin-PPARα, and rhoifolin-SREBP2. These findings suggest that JWXZ ameliorates HFD-induced MASLD mainly by rebalancing hepatic lipid metabolism through coordinated suppression of SREBP2-mediated cholesterogenesis and restoration of PPARα-mediated fatty acid oxidation, with associated attenuation of EGFR-linked inflammatory responses. - Source: PubMed
Ma YouchengGao XinruiWang JiLi LingruHuang ZhenLi Fangli